Chimeric VEGF-Binding Protein via AAV Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-angiogenic therapies, such as VEGF-trap molecules, have varying molecular sizes, binding affinities, and pharmacokinetics, requiring multiple administrations for sustained delivery and are hampered by tissue toxicity and low expression in gene-therapy approaches.
Innovation Solution
A chimeric VEGF-binding protein comprising a single immunoglobulin-like domain from the Flt-1 tyrosine kinase receptor and the Fc region of immunoglobulin G1, delivered via adeno-associated virus, effectively inhibits tumor growth by binding VEGF and providing sustained anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple VEGF-trap molecules are administered systemically to maintain sustained delivery, then therapeutic effectiveness is improved, but treatment complexity and patient burden increase
Solution Approach 1:
The patent employs gene therapy to enable the body's own cells to produce the VEGF-trap molecule continuously. By delivering the gene encoding the VEGF-trap (comprising Ig-like domains 2 and 3 of Flt-1 and the Fc region of IgG1) via viral vectors or non-viral methods, the therapeutic protein is produced endogenously, eliminating the need for repeated external administrations and achieving sustained anti-angiogenic activity
Solution Approach 2:
The patent performs preliminary action by delivering the gene construct before the need for sustained therapeutic effect arises. The gene is introduced into host cells in advance, establishing a permanent or long-lasting production capability that will continuously supply the VEGF-trap molecule, thereby preparing the system for sustained delivery without requiring multiple subsequent interventions
2Duration of action of moving object
If adenovirus-based gene therapy is used to deliver VEGF-trap, then sustained delivery is improved, but tissue toxicity increases
Solution Approach 1:
The patent changes the key parameter of the viral vector system by switching from adenovirus to adeno-associated virus (AAV). This parameter change fundamentally alters the safety profile while maintaining sustained delivery capability. AAV vectors provide long-term gene expression without the severe tissue toxicity and immune responses associated with adenovirus, thereby resolving the contradiction between sustained delivery and tissue safety
Solution Approach 2:
The patent employs disposable, non-integrating AAV vectors that deliver the gene therapy payload and then are cleared from the body. These viral vectors serve their purpose of gene delivery and are subsequently eliminated, avoiding persistent presence and associated toxicity. The therapeutic effect is sustained through endogenous protein production rather than persistent viral presence
3Duration of action of moving object
If adenovirus-based gene therapy is used to deliver VEGF-trap, then sustained delivery is improved, but transgene expression decreases
Solution Approach 1:
The patent changes the viral vector parameter from adenovirus to AAV, which fundamentally improves transgene expression levels. AAV vectors are capable of long-term persistent expression of the VEGF-trap gene in post-mitotic cells, achieving both sustained delivery and high transgene expression. This parameter change resolves the contradiction by providing a vector system that maintains both long duration and high expression quantity
4Reliability
If VEGF-trap molecules with varying molecular sizes are used, then binding affinity is improved, but pharmacokinetics become unpredictable
Solution Approach 1:
The patent employs a standardized, universal molecular architecture for the VEGF-trap consisting of Ig-like domains 2 and 3 of Flt-1 fused to the Fc region of IgG1. This universal design provides consistent pharmacokinetic properties across all instances of the therapeutic molecule, including predictable half-life, distribution, and clearance. The Fc portion confers universal characteristics such as extended circulation time through FcRn recycling, eliminating pharmacokinetic variability while maintaining high binding affinity through the standardized VEGF-binding domains
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric VEGF-binding protein achieves potent anti-tumor activity with improved pharmacokinetics and reduced immunogenicity, inhibiting tumor growth and angiogenesis in multiple tumor models with prolonged serum presence.
Implementation Method 1
delivered via intramuscular injection of adeno-associated virus expressing the protein
Implementation Method 2
a chimeric protein comprising a single immunoglobulin-like domain (Ig-like) derived from the vascular endothelial growth factor receptor tyrosine kinase Flt-1 and the fragment crystallizable (Fc) constant region of an immunoglobulin has potent anti-tumor activity
Data Source
AI summary
Provided are chimeric VEGF-binding proteins and nucleic acids (e.g., a vector) encoding chimeric VEGF-binding proteins, methods and host cells for producing these proteins and nucleic acids, and pharmaceutical compositions containing these proteins and nucleic acids. Also provided are methods of treating an angiogenic disease or disorder that include administering at least one of the chimeric VEGF-binding proteins or at least one of the nucleic acids (e.g., a vector) encoding a chimeric VEGF-binding protein.